Eli Lilly: buys Scorpion Therapeutics' PI3Kα program

(CercleFinance.com) - Eli Lilly and Company announces the acquisition of Scorpion Therapeutics' PI3Kα program, including the inhibitor STX-478, an oral treatment in Phase 1/2 clinical trials for breast cancer and other solid tumors.


STX-478 is distinguished by its ability to selectively target cancer cells, offering the potential for improved efficacy and tolerability.

The acquisition, worth up to $2.5bn, includes an upfront payment and payments linked to regulatory and commercial milestones.

Scorpion will spin off its other assets into a new entity, majority-owned by its current shareholders, with a minority stake from Lilly.

The transaction's completion is subject to customary conditions.


Copyright (c) 2025 CercleFinance.com. All rights reserved.